Welcome, Guest |
TOPIC:
Prof Gane's remarks: implications for relapse 8 years 21 hours ago #15349
| That is the question. Gane should prove Gilead is superior, since that seems to be what he implied. Gt 1a, F0, VL 6.5 million, AST 59, ALT 62 Started Twinvir 1/15/16 6 wk. labs VL UND, AST 27, ALT 20 EOT labs VL UND, AST 23, ALT 19 SVR 16, VL UND, AST 28, ALT 17 SVR 24 , VL UND, 10/8/16 SVR 125, VL UND, 9/22/18 SVR 230, VL UND, 10/3/20 |
Prof Gane's remarks: implications for relapse 8 years 19 hours ago #15362
| Hello, this is Asif from Incepta. We use 1:1 solid dispersion of Ledipasvir with Copovidone where Ledipasvir is in the amorphous form. This is exactly same as that of the innovator. We don't make our API, we source it from China. I wouldn't say our drug provides 100% success rate, no drug does. But we know a number of patients achieving SVR 12 with Twinvir. Asif Mostafa M. Pharm (DU), MBA (IBA) Senior Brand Manager Incepta Pharmaceuticals Ltd. 40 Shahid Tajuddin Sharani,Tejgaon 1/A, Dhaka-1208 Phone:8891688-703 (Ex. 155) Fax: +880-2-8891190 Mobile: +88-01713-338492 Available at Viber and whatsapp E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. |
Prof Gane's remarks: implications for relapse 8 years 9 hours ago #15385
I imagine Gilead sources from China as well. They want to make as much money as possible and if "Made in China" works for them..... I think the main Gane refrain is "The Gilead ledipasvir is real. I can't say the same about all ledipasvir." m This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 The following user(s) said Thank You: Gaj, Asif Mostafa | |
Time to create page: 0.070 seconds